This human study research adhered to the tenets of the Declaration of Helsinki and was approved by the Institutional Review Board of the Children's Hospital of Wisconsin, with informed consent obtained for every subject. Eight patients were screened for deletions or duplications of the
PITX2 upstream region: three patients had classic Axenfeld-Rieger syndrome, three had syndromic Axenfeld-Rieger anomaly without dental or umbilical features, and two had isolated Axenfeld-Rieger syndrome. Previous screening of the
PITX2 coding sequence did not identify a causative mutation in these patients. The screening for the coding sequence mutations was performed by direct bidirectional DNA sequencing of PCR products encompassing all coding exons of
PITX2A, PITX2B, and
PITX2C isoforms using previously described gene-specific primers.
11 Six patients with classic Axenfeld-Rieger syndrome and previously identified
PITX2 mutations (four patients) or whole-gene deletion (two patients) were excluded from this analysis. Patients were screened using Affymetrix Genome-Wide Human SNP Array 6.0, as previously described
37 , and/or TaqMan assays (Applied Biosystems, Carlsbad, CA) for the
PITX2 region. The following
PITX2 probes were used for TaqMan assays: Hs00452261_cn (P1, located in the last exon of
PITX2), Hs00958157_cn (P2,
PITX2C promoter), Hs01402614_cn (P3, most 5′ end of
PITX2, exon 1), Hs04822300_cn (P4, located 110,366 kb 5′ of
PITX2), Hs04838001_cn (P5, located 284,481kb 5′ of
PITX2), and Hs04811562_cn (P6, located 649,476 upstream of
PITX2). Assays were carried out in accordance with manufacturer recommendations on a real-time PCR cycler (Corbett Rotor-Gene; Qiagen); the values were normalized to amplification of a reference gene (
RNase P) with both region-specific (P1-P6) and reference gene probes analyzed simultaneously in one reaction. Each experiment was performed in triplicate. Relative fold change in copy number in patient genome was determined using the ΔΔ CT quantification method and compared with the same measurement in an unaffected control sample.